Halozyme (NASDAQ:HALO) has raised its financial guidance estimates for 2025 based on expected strong sales of products formulated using its Enhanze drug delivery technology. The company now estimates ...
Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find out why I rate HALO stock a Buy.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full ...
TD Cowen analyst Brendan Smith reiterated a Buy rating on Halozyme (HALO – Research Report) today and set a price target of $77.00.Stay Ahead ...
Zacks Research increased their Q1 2025 EPS estimates for shares of Halozyme Therapeutics in a report released on Tuesday, ...
Leerink Partners analyst David Risinger maintained a Hold rating on Halozyme (HALO – Research Report) on January 12 and set a price target of ...
Halozyme (HALO) announced that Bristol Myers Squibb (BMY) received FDA approval for Opdivo Qvantig co-formulated with Halozyme’s Enhanze drug delivery technology for subcutaneous use in most ...
Leidos, Amazon.com, Halozyme Therapeutics and BioMarin Pharmaceutical are part of the Zacks Screen of the Week article.
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto ...